ondasdechoque.org
PT-BR

How might shockwaves ease musculoskeletal pain? A 2026 narrative review · Lab study · 2026

How might shockwave ease muscle, tendon and joint pain?

This review explains how shockwave might ease pain, mostly from animal and lab studies: by changing the small nerves that carry pain, calming inflammation and improving blood flow. It may also change how the brain handles pain, an idea that rests on very few studies.

Explores how shockwave works
conditions discussed, from low back pain to spasticity
9
brain imaging study in people behind the brain-pain idea
1
year published
2026

Good to know: A narrative review.

Gao T, Zhao B J Int Med Res, 2026 · Read the paper ↗

The treatment

Device types described
Focused ESWT is described as suited to deep-tissue lesions and radial ESWT to superficial soft-tissue lesions; the review tests no regimen.
Parameter statements (as reported)
Chronic pelvic pain: regimens of at least 2,000 pulses described as superior, citing one meta-analysis. Frequencies below 8 Hz and pressures below 2 bar described as optimal, citing a review of limb dysfunction after stroke. In rabbits with acute muscle injury, the 10 Hz group showed the largest fall in inflammatory mediators. A dose-escalation approach for plantar fasciitis is cited from one clinical study. The authors state that no unified standard exists.

Who took part

Earlier reviews and trials in people with back, knee, heel, shoulder, muscle, wrist or pelvic pain, or spasticity, and mechanism studies in rats, rabbits and cells.

Side effects

Mostly mild, short-lived local pain, redness and swelling; serious events are described as extremely rare.

All the numbers and the full appraisal
FROM THE FULL PAPER

What the full paper reports.

No new patient cohort. The review draws on systematic reviews, meta-analyses and trials in chronic low back pain, knee osteoarthritis, plantar fasciopathy, rotator cuff disease, myofascial pain, carpal tunnel syndrome, chronic pelvic pain, muscle injury and spasticity, on safety consensus papers, and on mechanism studies in rats, rabbits and cultured cells. The number of studies included is not stated.

Peripheral pain mechanisms1 reported outcome
01
As reported in the cited studies

Peripheral pain mechanisms

Qualitative finding

Selective degeneration and later regeneration of unmyelinated sensory fibres, lower PGE2 and IL-1β, and more blood flow through VEGF and eNOS are presented as analgesic mechanisms. For these, Table 2 lists a narrative review and preclinical animal studies (rat prostatitis, rabbit muscle injury, rat diabetic wounds); the text also cites a rat arthritis study and a cell-culture study. Human support comes indirectly from nerve-conduction findings in carpal tunnel syndrome meta-analyses and trials.

Analysis details and source

Evidence level as stated by the review; the cited studies were not retrieved. Animal and cell findings are not human treatment effects.

Brain pain-network (fMRI) claims1 reported outcome
02
As reported in the cited studies

Brain pain-network (fMRI) claims

Qualitative finding

The abstract presents modulation of central pain networks as a mechanism, and the introduction and conclusion name the somatosensory cortex, thalamus and anterior cingulate cortex. The only human imaging evidence cited is one clinical fMRI study in primary dysmenorrhoea that, as described, found changes in the left middle temporal gyrus; the other sources are a rat BOLD-fMRI study (cited in the text without naming the species; Table 2 labels it animal), a trial protocol and a cervical spondylosis trial cited for symptom changes. Claims that ESWT modulates central pain networks, reduces pain memory and restores nociceptive processing in the spinal dorsal horn and brainstem cite a clinical efficacy study in postherpetic neuralgia (pain and itch outcomes), not imaging or mechanism measurements. The authors call these data preliminary.

Analysis details and source

Region named for the human study comes from the review text; the regions named in the introduction and conclusion are not tied to a reported human finding.

Clinical efficacy statements and what they cite1 reported outcome
03
As reported in the cited studies

Clinical efficacy statements and what they cite

Qualitative finding

The review states that ESWT relieves pain and improves function in chronic low back pain, knee osteoarthritis, plantar fasciopathy, rotator cuff disease, myofascial pain, carpal tunnel syndrome, chronic pelvic pain, muscle injury and spasticity. Table 2 lists meta-analyses or systematic reviews for most of these, but the rotator cuff statements cite a systematic-review protocol and the 2020 Cochrane review, which the authors summarize as "moderate evidence" in support, although that review’s own published conclusion, based on low- to moderate-certainty evidence, found very few clinically important benefits for people with rotator cuff disease; one spasticity statement cites a review protocol and one knee osteoarthritis source is a trial protocol; fracture-repair claims cite a platelet-rich plasma combination study and a case report. No effect sizes, confidence intervals or participant numbers are given.

Analysis details and source

These are the authors’ summaries of other publications, not checked results; they are recorded to show what each claim rests on.

Safety and contraindications as reported1 reported outcome
04
As reported in the cited studies

Safety and contraindications as reported

Qualitative finding

Most adverse reactions are described as mild, self-limiting local pain, redness and swelling and severe events as extremely rare, citing a scoping review of 117 narrative reviews and a Delphi consensus. Absolute contraindications listed: malignant tumour or infection in the treatment area, pregnancy, and a pacemaker or implanted device near the target. Severe coagulopathy is a relative contraindication to high-energy treatment, and anticoagulation calls for an individual risk–benefit assessment. Evidence in children, older adults, immunocompromised people and people with cancer is described as limited to case reports and small studies.

Analysis details and source

Guidance summarized from consensus and guideline papers; no event counts are given.

How treatment was delivered
Device types described

Focused ESWT is described as suited to deep-tissue lesions and radial ESWT to superficial soft-tissue lesions; the review tests no regimen.

Parameter statements (as reported)

Chronic pelvic pain: regimens of at least 2,000 pulses described as superior, citing one meta-analysis. Frequencies below 8 Hz and pressures below 2 bar described as optimal, citing a review of limb dysfunction after stroke. In rabbits with acute muscle injury, the 10 Hz group showed the largest fall in inflammatory mediators. A dose-escalation approach for plantar fasciitis is cited from one clinical study. The authors state that no unified standard exists.

HARMS & TOLERABILITY

No new harms data. The review states that adverse reactions are mostly mild, transient local pain, redness and swelling and that severe events are extremely rare, citing a scoping review and a Delphi consensus, without event counts or rates; safety data in children, older adults, immunocompromised people and people with cancer are described as limited.

LIMITS OF THE ANALYSIS

Author-reported: the narrative design may have missed relevant studies and excluding non-English publications may have introduced language bias; heterogeneity in study design, ESWT parameters and outcomes prevents firm conclusions and quantitative synthesis; evidence in fracture rehabilitation and vulnerable populations is limited and should be regarded as preliminary.

Extractor: no count of included studies, selection flow, risk-of-bias appraisal or effect sizes; SANRA is cited without scores. The conclusion that ESWT is "effective and well-tolerated", with the strongest support in five named conditions, repeats the cited reviews without appraising them. It names rotator cuff disease among those five, although its own cited 2020 Cochrane review concluded that shock wave therapy gave very few clinically important benefits.

Extractor: citation and labelling problems. Protocols are cited as if they reported results (references 8, 10 and 20); a case report (reference 45) is cited although case reports were an exclusion criterion; Table 2 labels the scoping review (reference 24) as a Delphi consensus and as a Cochrane review, and the Cochrane review (reference 23) as a narrative review, and gives the cerebral palsy references as 27–29 where the text cites 26–28; a rat fMRI study is cited for brain-network effects without naming the species; frequency and pressure limits from a stroke-rehabilitation review are applied to pain; a "more than 50%" faster muscle-injury recovery is compared with literature reports, not with a control group.

Funding: a school-level research project of Dali Nursing Vocational College and the Science Research Project of the Dali Prefecture Science and Technology Bureau. Conflicts: none declared; no device-maker ties are reported. The authors acknowledge AI-assisted language editing.

Findings checked against the full source by a separate automated reviewer.

Limitations noted by the reviewers

  • Author-reported: the narrative design may have missed relevant studies and excluding non-English publications may have introduced language bias; heterogeneity in study design, ESWT parameters and outcomes prevents firm conclusions and quantitative synthesis; evidence in fracture rehabilitation and vulnerable populations is limited and should be regarded as preliminary.
  • Extractor: no count of included studies, selection flow, risk-of-bias appraisal or effect sizes; SANRA is cited without scores. The conclusion that ESWT is "effective and well-tolerated", with the strongest support in five named conditions, repeats the cited reviews without appraising them. It names rotator cuff disease among those five, although its own cited 2020 Cochrane review concluded that shock wave therapy gave very few clinically important benefits.
  • Extractor: citation and labelling problems. Protocols are cited as if they reported results (references 8, 10 and 20); a case report (reference 45) is cited although case reports were an exclusion criterion; Table 2 labels the scoping review (reference 24) as a Delphi consensus and as a Cochrane review, and the Cochrane review (reference 23) as a narrative review, and gives the cerebral palsy references as 27–29 where the text cites 26–28; a rat fMRI study is cited for brain-network effects without naming the species; frequency and pressure limits from a stroke-rehabilitation review are applied to pain; a "more than 50%" faster muscle-injury recovery is compared with literature reports, not with a control group.
  • Funding: a school-level research project of Dali Nursing Vocational College and the Science Research Project of the Dali Prefecture Science and Technology Bureau. Conflicts: none declared; no device-maker ties are reported. The authors acknowledge AI-assisted language editing.
Research review

Source-linked critical reading

Narrative review

Reading depthMaterial consulted
Technical source record

Complete local PDF read (13 pages), including all sections, Tables 1–2, acknowledgments, funding, conflict declaration and all 62 references. The cited studies were not retrieved.

Review statusAI-assisted draft · independent automated checkThis automated check comes before the editor’s clinical review.
Study design

Narrative review that searched PubMed, Web of Science and Scopus for English-language articles published through 2025 and says it followed the SANRA checklist. It does not report how many studies were included, a selection flow, a risk-of-bias appraisal or any pooled estimate. Table 2 assigns levels of evidence to the cited references.

Participants and setting

No new patient cohort. The review draws on systematic reviews, meta-analyses and trials in chronic low back pain, knee osteoarthritis, plantar fasciopathy, rotator cuff disease, myofascial pain, carpal tunnel syndrome, chronic pelvic pain, muscle injury and spasticity, on safety consensus papers, and on mechanism studies in rats, rabbits and cultured cells. The number of studies included is not stated.

Treatment

No regimen was tested. Focused ESWT is described for deep lesions and radial ESWT for superficial soft tissue. Parameter statements (for example, at least 2,000 pulses in chronic pelvic pain, or below 8 Hz and 2 bar) come from individual cited reviews, and the authors state that no unified standard exists.

Comparison

The review makes no new comparison. Cited studies compared ESWT with sham, local corticosteroid injection, other physical therapies, or medication or physiotherapy alone, or had no control; one muscle-injury study compared recovery with times reported in earlier literature.

Outcomes and timing

Narrative summaries, as described by the cited studies, of pain intensity and function, nerve conduction, brain imaging, inflammatory and vascular markers in animals, and adverse events. No numerical results are extracted or pooled.

What the results show

The review proposes peripheral mechanisms (loss and regrowth of small sensory nerve fibres, fewer inflammatory mediators, more blood flow), supported mainly by rat, rabbit and cell studies and an earlier narrative review, and central effects on brain pain networks, supported by one human imaging study, one rat imaging study and a trial protocol. Its efficacy statements cite meta-analyses for several conditions but give no effect sizes, the rotator cuff claims cite a review protocol and a Cochrane review whose own conclusion found very few clinically important benefits, and one spasticity statement cites a review protocol rather than results. Reported side effects were mostly mild, short-lived local pain, redness and swelling.

Harms

No new harms data. The review states that adverse reactions are mostly mild, transient local pain, redness and swelling and that severe events are extremely rare, citing a scoping review and a Delphi consensus, without event counts or rates; safety data in children, older adults, immunocompromised people and people with cancer are described as limited.

Limits and disclosures

Narrative review without a count of included studies, selection flow or risk-of-bias appraisal; SANRA is cited but no score is reported. Mechanism claims rest mainly on animal and cell studies; the brain-network claim rests on one human fMRI study, a rat fMRI study that the text cites for brain-network effects without saying it was done in rats (Table 2 labels it animal), and a protocol. Several clinical claims cite protocols (rotator cuff, spasticity, a knee osteoarthritis trial) or a case report although case reports were excluded; Table 2 mislabels some references; frequency and pressure limits for pain are taken from a stroke-rehabilitation review. Funded by local college and prefecture research grants; no conflicts declared; AI-assisted language editing acknowledged.

Application to care

A map of proposed mechanisms, conditions studied and contraindication guidance. It cannot estimate how much a particular person’s pain will improve, choose a dose, or stand in for condition-specific systematic reviews.

What remains to be tested

Large multicentre randomized trials with standardized parameters, long follow-up and core outcome sets, and human studies that link nerve, inflammatory or brain-imaging changes to pain outcomes, as the authors propose; blinded outcome assessment would strengthen them.

THE ORIGINAL SOURCE

Read the original article.

Narrative review: Extracorporeal shock wave therapy for pain management in musculoskeletal rehabilitation: Mechanisms, clinical applications, and safety.

Gao T, Zhao B. · J Int Med Res · 2026

Open the publication record or available full-text files.

Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →